LIBRETTO-432: A Phase 3 Study of Adjuvant Selpercatinib or Placebo in Stage IB-IIIA RET Fusion-Positive (RET+) NSCLC.
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined